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Loss of renal function and microvascular blood
flow after suprarenal aortic clamping and
reperfusion (SPACR) above the superior
mesenteric artery is greatly augmented compared
with SPACR above the renal arteries
Stuart I. Myers, MD,a,b Li Wang, BS,a and Daniel J. Myers,a Richmond, Va; and Chattanooga, Tenn
Objective: Renal insufficiency continues to be a complication that can affect patients after treatment for suprarenal
aneurysms and renal artery occlusive disease. To our knowledge, no data are available showing that suprarenal aortic
clamping and reperfusion (SRACR) above the renal arteries (renal-SRACR) preserves renal function compared with
SRACR above the superior mesenteric artery (SMA-SRACR). This study examined the hypothesis that SMA-SRACR–
induced downregulation of renal blood flow and function is more severe than renal-SRACR owing to the addition of
systemic oxygen-derived free radical (ODFR) release.
Methods:Male Sprague-Dawley rats (about 350 g) were anesthetized andmicrodialysis probes or laser Doppler fibers were
inserted into the renal cortex (depth of 2 mm) and into the renal medulla (depth of 4 mm). Laser Doppler blood flow was
continuously monitored, and the microdialysis probes were connected to a syringe pump and perfused in vivo at 3
L/min with lactated Ringer’s solution.
Results: SMA-SRACR and Renal-SRACR decreased medullary and cortical blood flow and nitric oxide (NO) synthesis.
SMA-SRACR downregulated cortical inducible NO synthase, whereas renal-SRACR did not. The cortex and medulla
responded to the decreased blood flow and NO synthesis by increasing in prostaglandin E2 synthesis, which was due to
increased cyclooxygenase-2 content. Superoxide dismutase restored SMA-SRACR (but not renal-SRACR) cortical and
medullary NO synthesis, suggesting that ODFRs generated during mesenteric ischemia–reperfusion were one of the
systemic mechanisms contributing to decreased renal NO synthesis in the SMA-SRACR model. The 90% decrease in
creatinine clearance after SMA-SRACR was greater than the 60% decrease after renal-SRACR.
Conclusions: These data show that NO is important in maintaining renal cortical and medullary blood flow and NO
synthesis after renal and SMA-SRACR. These data also suggest that in addition to the renal ischemia–reperfusion caused
by both models, SMA SRACR induces mesenteric ischemia–reperfusion, resulting in the generation of ODFRs, which
contribute to decreased renal cortical and medullary NO synthesis. Maintaining splanchnic blood flow or attempting to
keep SRACR below the SMA level may be helpful in developing strategies to minimize the renal injury after SRACR.
(J Vasc Surg 2007;45:357-66.)
Clinical Relevance: This study suggests that clinically relevant cortical and medullary vasodilators (nitric oxide and
vasodilator prostanoids) are required to maintain microvascular renal cortical and medullary blood flow after superior
mesenteric artery suprarenal aortic clamping and reperfusion (SRACR) both above the superior mesenteric artery (SMA)
and above the renal arteries (Renal-SRACR). The data strongly suggest that the renal injury after SMA-SRACR is worse
than that after renal-SRACR. The more severe injury caused by SMA-SRACR is partly mediated by oxygen-derived free
radicals that were not involved with the renal injury after renal-SRACR. Maintaining SMA blood flow and preventing or
inhibition of oxygen-derived free radical production during SMA-SRACR should be one treatment strategy that could
help maintain renal microvascular blood flow during the treatment of complex aortic pathology that require SRACR.Renal dysfunction continues to be a frequent compli-
cation of suprarenal aortic reconstruction.1-3 One of the
major limitations to decreasing the incidence of renal dys-
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doi:10.1016/j.jvs.2006.10.045function after suprarenal aortic clamping has been the lack
of insight into the pathophysiology of renal injury that
occurs after clamping and reperfusion of the aorta at differ-
ent levels Nitric oxide (NO),4-10 prostaglandin E2 (PGE2),
and prostacyclin (PGI2; vasodilator eicosanoids)
11-14 have
been proposed as important endogenous mediators that
contribute to arterial dilatation of the renal microvascular
bed and maintenance of renal blood flow. Loss of these
potent renal vasodilators has been associated with renal
vasoconstriction after infrarenal aortic clamping and reper-
fusion and renal ischemia–reperfusion injury.15-22
Oxygen-derived free radicals (ODFRs) have been impli-
cated in the pathogenesis of renal injury induced by ischemia–
reperfusion.23 ODFRs have been proposed as important me-
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reperfusion injury and during the peroxidase-catalyzed
enzymatic reduction of hydroperoxy fatty acids (endoperox-
ide). The highly reactive ODFRs inhibit eicosanoid and NO
synthesis, which could lead to decreased renal blood flow and
function.23-27
We recently combined the use of in vivo microdialysis
and laser Doppler blood flow analyses to identify clinically
relevant intrarenal vasodilators (cortical and medullary)
that are required tomaintain microvascular blood flow after
superior mesenteric artery (SMA) suprarenal aortic clamp-
ing and reperfusion (SRACR). The findings of this study
showed SMA-SRACR caused a profound decrease in med-
ullary and cortical blood flow with a concomitant decrease
in endogenous medullary and cortical NO synthesis and
renal function.19
Whether renal-SRACR induces the same alterations in
renal physiology and function as was shown after SMA-
SRACR is not known. This study examines the hypothesis
that the downregulation of renal blood flow and function
induced by SMA-SPACR is more severe than renal-SRACR
and this is partly due to the generation of ODFRs during
the mesenteric ischemia–reperfusion injury.
MATERIALS AND METHODS
Animal model. All animal surgery and care was per-
formed using the established guidelines approved by the
Institutional Animal Care and Use Committee, the
McGuire VA Medical Center, Richmond, Virginia. Male
Sprague-Dawley rats (about 350 g; Harlan, Indianapolis,
Ind) were anesthetized with 2% isoflurane vaporized by
oxygen. The rats were placed on a small-animal operating
table with a fixed bar clamp holding a Lucite kidney cup for
isolation of the kidney from movement. This allowed for
precise placement of cortical and medullary laser fiber
probes with micropositioners. Microdialysis catheters were
also placed through the renal cortex and medulla in sepa-
rate groups.
The right femoral artery was cannulated, heparinized
(100 U/kg), and connected to a blood pressure analyzer
(BPA; Digimed, Louisville, Ky) for constant monitoring of
heart rate and arterial blood pressure. Perivascular ultra-
sonic blood flow probes (Transonic Systems, Inc, Ithaca,
NY) were placed around the renal artery and the abdominal
aorta, and data were collected as milliliters per minute.
Body temperature was monitored by using rectal tempera-
ture probe.
The animal’s abdomen was filled with saline and lubri-
cating jelly to insulate contact between blood flow probes
and blood vessels. Either microdialysis probes or laser
Doppler fibers were inserted into the renal cortex (depth of
2 mm) and into the renal medulla (depth of 4 mm; see next
paragraph for detail). The laser Doppler blood flow and
microdialysis groups were treated with saline carrier, indo-
methacin (cyclooxygenase [COX]-1 and COX-2 inhibitor,
10 mg/kg intravenous), N-nitro-L-arginine methyl ester
hydrochloride (L-NAME; 30 mg/kg, NOS inhibitor), L-
arginine (400 mg/kg, NO precursor), or superoxide dis-mutase (SOD, 10,000 U/kg, ODFR scavenger).17,19,20
SOD was given 30 minutes before the reperfusion, and the
other drugs were given 15 minutes before reperfusion. The
renal cortex and medulla were separated and analyzed for
inducible nitric oxide synthase, COX-2, prostacyclin syn-
thase (PS), and prostaglandin (PG) E2 synthase content by
Western blot.
Microdialysis probes in vivo perfusion. Microdialysis
probes were prepared in advance as previously de-
scribed.19,20,28,29 One microdialysis probe was inserted
into the renal cortex to a depth of 2 mm and another into
the renal medulla at 4mm. These probes were connected to
a syringe pump and perfused at a rate of 3 L/min with
lactated Ringer’s solution. Dialysate fluid was collected at
basal time zero and after 30 minutes of aortic clamping
above the superior mesenteric artery (SMA-SRACR) or
renal artery (renal-SRACR), followed by 60 minutes of
reperfusion and compared with sham operation.
Dialysate samples were collected and frozen at 80°C
until assayed for total NO (M), PGE2, 6-keto-PGF1
(PGI2 metabolite), and thromboxane B2 (TxB2, throm-
boxane A2 metabolite) synthesis. Data are reported as
percentage change of each substance after the 30 minutes
of aortic clamping and 60minutes of reperfusion compared
with the baseline time zero. Use of the microdialysis probes
allowed NO, PGE2, 6-keto-PGF1 and thromboxane B2 to
diffuse in and out of the dialysis probe, depending on the
local concentration. Because NO and the eicosanoids mea-
sured are not stored within the cell, release of these sub-
stances represent de novo synthesis. After completion of
each experiment, the kidneys were opened to confirm
accurate placement of the microdialysis probes.
Laser Doppler renal cortical and medullary blood
flow analysis. The right kidney was isolated and placed in
a 21-mm Lucite kidney cup. Ultrasonic blood flow probes
(Transonic Systems, Inc) were placed around the renal
artery and abdominal aorta, and data were collected as
milliliters per minute. Body temperature was monitored by
using a rectal probe. Micropositioners were used to insert
the shallow (2 mm-cortical) and deep (4 mm-medullary)
calibrated laser fiber probes. Position of the fibers within
the kidneys was checked after each experiment.
A Periflux 4001 Dual Channel Laser Doppler flowme-
ter (Perimed, Järfälla, Sweden) was used to evaluate micro-
vascular perfusion. Measurements were expressed as arbi-
trary perfusion units, which represent the product of the
velocity and the concentration of moving blood cells within
the measuring volume. After a 5-minute equilibration pe-
riod, basal readings were recorded and subsequent readings
recorded every 10 minutes throughout the SMA-SRACR,
renal-SRACR, and sham procedures.18-21 Data are re-
ported as percentage change of cortical or medullary blood
flow after the 30 minutes of supra-SMA or supra-renal
aortic clamping and 60 minutes of reperfusion compared
with the baseline time zero.
Enzyme immunoassays. The renal microdialysis ef-
fluent was frozen at80°C until assayed for PGE2, 6-keto-
PGF1, and thromboxane B2 by an enzyme immunoassay
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run in duplicate and reported as picograms of eicosanoid
measured per milliliter (mean  SEM). Data were then
converted to and reported as percentage change compared
with baseline at time zero.
Nitric oxide analysis. A Sievers 280 NOA Nitric Ox-
ide Analyzer with Radical Purger (Sievers Instruments,
Boulder, Colo) was used to detect NO (M) and its
reaction products in biologic samples. The technique used
for the measurement of NO and its oxidation products was
the reduction of nitrate, nitrite, and nitrosothiols using
vanadium (III) and hydrochloric acid at 90°C.19,20 The
data are reported as percentage change compared with
baseline time zero.
Protein assays. The kidneys from sham, SMA-
SRACR, and renal-SRACR groups were harvested and
placed on ice. Cortical and medullary tissues were rapidly
separated, frozen in liquid nitrogen, and stored at 80°C
until assayed for protein. Tissues were thawed in a phos-
phate buffer, homogenized, and centrifuged at 4°C for 20
minutes. Supernatants were decanted, and total protein was
determined by the Bradford method30 using protein assay
dye reagent concentrate (Bio-Rad Laboratories, Hercules,
Calif). A 5 sodium dodecyl sulfate (SDS) sample buffer
(1  62.5 mM Tris-HCl, pH 8.0; 2% SDS; 0.025%
bromophenol blue; 20% glycerol; 5% -mercaptoethanol)
was added to the protein samples and stored at0°C until
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Fig 1. The effects of superior mesenteric artery (SMA) suprarenal
aortic clamping and reperfusion (SRACR) and renal-SRACR on
renal cortical blood flow. Laser Doppler probes were placed 2 mm
into the cortex and blood flow was continuously monitored at
basal time period and after 30 minutes of suprarenal aortic clamp-
ing, followed by 60 minutes of reperfusion, and compared with
sham operation. The ischemia–reperfusion (IR) groups (n  8
each) were treated with carrier, indomethacin (intravenous
cyclooxygenase-1 and cyclooxygenase-2 inhibitor, 10 mg/kg),
N-nitro-L-arginine methyl ester hydrochloride (L-NAME; 30
mg/kg, nitric oxide synsthase inhibitor), L-arginine (400 mg/kg,
nitric oxide precursor), or superoxide dismutase (SOD; 10,000U/
kg, oxygen-derived free radical scavenger). Data are reported as
percentage change from basal time zero and expressed as mean 
SEM. (a, indicates significance at P	 .05 compared with sham; b,
indicates significance at P 	 .05 compared with the IR group
without drug treatment; d, indicates significance at P 	 .05 com-
pared with the L-NAME group at P 	 .05.)assayed by Western blot.Sodium dodecyl sulfate polyacrylamide gel electro-
phoresis/Western blot analyses. Protein samples diluted
in SDS sample buffer were solubilized by boiling for 4
minutes. Aliquots (25 g) were loaded into gel lanes of a
vertical electrophoretic unit (Bio-Rad), and protein separa-
tion by molecular weight was done on 1-mm 7% polyacryl-
amide resolving gel with a 1-mm 3% stacking gel by the
Laemmli method,31 which includes prestained molecular
weight standard markers (Sigma, St Louis, Mo). Proteins
were then transferred from the resolving gels to nitrocellu-
lose membranes (Schleicher & Schuell, Keene, NH), as
described by Burnette,32 using a Trans-Blot electro-
phoretic transfer cell (Bio-Rad) operating at 100 mA for 18
hours at 4°C.
The membranes were incubated for 1 hour at room
temperature in blocking buffer (buffer B:10 mM sodium
phosphate, 0.5 M sodium chloride, 10% bovine serum
albumin, 0.05% Tween 20) and subsequently overnight at
room temperature in buffer B containing a primary anti-
body,15,33 -cyclooxygenase-2 polyclonal antiserum (Cay-
man Chemical Co), PGE2 synthase (Cayman Chemical
Co), prostacyclin synthase (-prostacyclin synthase poly-
clonal antiserum donated by Dr William Smith, Michigan
State University, East Lansing), or -inducible nitric oxide
synthase antiserum (Oxford Biomedical Research, Inc.,
Oxford, Mich).
The nitrocellulose membranes were then washed of
excess primary antibody at room temperature in phosphate-
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Fig 2. The effects of superior mesenteric artery (SMA) suprarenal
aortic clamping and reperfusion (SRACR) and renal-SRACR on
renal medullary blood flow. Laser Doppler probes were placed 4
mm into the medulla and blood flow was continuously monitored
at basal time period and after 30 minutes of supra-renal aortic
clamping, followed by 60 minutes of reperfusion, and compared
with sham operation. The ischemia–reperfusion (IR) groups (n
8 each) were treated with carrier, indomethacin (intravenous
cyclooxygenase-1 and cyclooxygenase-2 inhibitor, 10 mg/kg),
N-nitro-L-arginine methyl ester hydrochloride (L-NAME; 30
mg/kg, nitric oxide synthase inhibitor), L-arginine (400 mg/kg,
nitric oxide precursor), or superoxide dismutase (SOD; 10,000U/
kg, oxygen-derived free radical scavenger). Data are reported as
percentage change from basal time zero and expressed as mean 
SEM. (a, indicates significance at P	 .05 compared with sham; b,
indicates significance at P 	 .05 compared with the IR group
without drug treatment; d, indicates significance at P 	 .05 com-
pared with the L-NAME group at P 	 .05.)buffered saline Tween buffer (PBST: 10 mM potassium
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20) and incubated for 1 hour at room temperature in buffer
B and secondary antibody, goat -rabbit immunoglobulin
G horseradish peroxidase (Bio-Rad). The membranes were
washed of secondary antibody at room temperature in
PBST and incubated in chemiluminescence reagent (Re-
naissance, DuPont-NEN, Boston, Mass) for 1 minute.
They were inserted into a plastic sheet protector, bubbles
were removed, and they were placed against autoradiogra-
phy film (Kodak, Rochester, NY). The film exposure times
were adjusted to obtain the ideal density of bands identify-
ing the enzymes of interest and an imaging system (Alpha
Innotech, San Leandro, Calif) was used to measure these
bands by spot densitometry.
Creatinine clearance. Separate groups of animals
were used to measure serum creatinine, urine creatinine,
and urine volume.15,19,20 These groups underwent supra-
SMA and suprarenal aortic clamping (and sham), followed
by reperfusion but the microdialysis probes or laser Dopp-
ler fibers were not placed in the kidneys. These groups were
subjected to saline carrier, intravenous indomethacin
(COX-1 and COX-2 inhibitor, 10 mg/kg), L-NAME (30
mg/kg, NOS inhibitor), L-arginine (400 mg/kg, NO
precursor), or SOD (10,000 U/kg, ODFR scavenger), as
described previously. Serum and urinary creatinine were
measured by a SYNCHRONLC System (BeckmanCoulter
Inc, Fullerton, Calif), and data are reported as milliliters per
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Fig 3. The effects of superior mesenteric artery (SMA) suprarenal
aortic clamping and reperfusion (SRACR) and renal-SRACR on
renal cortical nitric oxide release. Microdialysis probes were placed
2 mm into the cortex, connected to a syringe pump, and perfused
in vivo at 3 L/min with lactated Ringer’s solution. Dialysate fluid
was collected at basal time zero and after 30 minutes of supra-renal
aortic clamping, followed by 60 minutes of reperfusion, and com-
pared with sham operation. The ischemia–reperfusion (IR) groups
(n 8 each) were treated with carrier, indomethacin (intravenous
cyclooxygenase-1 and cyclooxygenase-2 inhibitor, 10 mg/kg),
N-nitro-L-arginine methyl ester hydrochloride (L-NAME; 30
mg/kg, nitric oxide synthase inhibitor), L-arginine (400 mg/kg,
nitric oxide precursor), or superoxide dismutase (SOD; 10,000U/
kg, oxygen-derived free radical scavenger). Data are reported as
percentage change from basal time zero and expressed as mean 
SEM. (a, indicates significance at P	 .05 compared with sham; b,
indicates significance at P 	 .05 compared with the IR group
without drug treatment; d, indicates significance at P 	 .05 com-
pared with the L-NAME group at P 	 .05.)minute.Statistical analysis. The NO and eicosanoid release
data and the laser blood flow data are converted to percent-
age of original basal time to control for any intraexperimen-
tal variation. Western blot results are expressed as densi-
tometry units, and the creatinine clearance is expressed as
milliliters per minute. The heart rate is recorded as beats per
minute and themean blood pressure inmmHg. All data are
expressed as mean  SEM. An n  8 is used for all groups
and specifically identified in each figure legend. Analysis of
variance and Student’s t tests were used to determine
differences among the groups; a value of P 	 .05 was
considered statistically significant.
RESULTS
Although the data are not shown, SMA-SRACR and
renal-SRACR did not significantly alter mean blood pres-
sure or heart rate compared with the sham groups. These
data are similar to the data presented in our previous
work.19
Renal-SRACR and SMA-SRACR decreased renal cor-
tical blood flow compared with the sham group (Fig 1).
Treatment of the experimental groups with indomethacin
further decreased cortical blood flow after SMA-SRACR
but not after renal-SRACR. Treatment of the experimental
groups with SOD improved renal cortical blood flow after
SMA-SRACR but not after renal-SRACR. These findings
0.0
0.5
1.0
1.5
RENAL
SMA
N
itr
ic
 
O
x
id
e 
( µµ µµ
M
)
IR  IR+
Indo
   IR+
L-NAME
  IR+
L-Arg
a
Sham  IR+
SOD
a
a
b
a
b,d
a
b
a
Fig 4. The effects of superior mesenteric artery (SMA) suprarenal
aortic clamping and reperfusion (SRACR) and renal-SRACRon renal
medullary nitric oxide release.Microdialysis probes were placed 4mm
into themedulla, connected to a syringe pump, andperfused in vivo at
3 L/min with lactated Ringer’s solution. Dialysate fluid was col-
lected at basal time zero, after 30 minutes of supra-renal aortic
clamping, followed by 60minutes of reperfusion, and compared with
sham operation. The ischemia–reperfusion (IR) groups (n 8 each)
were treated with carrier, indomethacin (intravenous cyclooxygen-
ase-1 and cyclooxygenase-2 inhibitor, 10 mg/kg), N-nitro-L-
arginine methyl ester hydrochloride (L-NAME; 30 mg/kg, nitric
oxide synthase inhibitor), L-arginine (400 mg/kg, nitric oxide pre-
cursor), or superoxide dismutase (SOD; 10,000U/kg, oxygen-
derived free radical scavenger). Data are reported as percentage
change from basal time zero and expressed as mean  SEM. (a,
indicates significance at P 	 .05 compared to sham; b, indicates
significance at P 	 .05 compared with the IR group without drug
treatment; d, indicates significance at P 	 .05 compared with the
L-NAME group at P	 .05.)suggest that SMA-SRACR downregulated synthesis of an
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same time upregulated splanchnic ODFR production that
contributed to downstream decreased renal cortical blood
flow.15
Treatment of the animals with L-NAME during SMA-
SRACR and renal-SRACR significantly decreased cortical
blood flow compared with the sham group without drug
treatment. Treatment of the animals with L-arginine before
SMA-SRACR and renal-SRACR significantly lessened the
decrease in cortical and medullary blood flow after reperfu-
sion compared with the L-NAME groups (Fig 1). These
findings suggest that endogenous NO and endogenous
vasodilator splanchnic prostanoids contribute to maintain-
ing cortical blood flow in both models.
Renal-SRACR and SMA-SRACR both decreased renal
medullary blood flow compared with the sham group (Fig
2). Treatment of the experimental groups with indometh-
acin significantly decreased medullary blood flow after
SMA-SRACR but not after renal-SRACR. SOD did not
alter renal medullary blood flow after SMA-SRACR or
renal-SRACR. Treatment of the animals with L-NAME
during SMA-SRACR and renal-SRACR significantly de-
creased medullary blood flow compared with the ischemia–
reperfusion group without drug treatment (Fig 2). Treat-
ment of the animals with L-arginine before SMA-SRACR
and renal-SRACR significantly lessened the decrease in
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Fig 5. The effects of superior mesenteric artery (SMA) suprarenal
aortic clamping and reperfusion (SRACR) and renal-SRACRon renal
cortical prostaglandin E2 (PGE2) release. Microdialysis probes were
placed 2 mm into the cortex, connected to a syringe pump, and
perfused in vivo at 3 L/min with lactated Ringer’s solution. Dialy-
sate fluid was collected at basal time zero, after 30 minutes of supra-
renal aortic clamping, followed by 60 minutes of reperfusion, and
compared with sham operation. The ischemia–reperfusion (IR)
groups (n  8 each) were treated with carrier, indomethacin (intra-
venous cyclooxygenase-1 and cyclooxygenase-2 inhibitor, 10 mg/
kg), N-nitro-L-arginine methyl ester hydrochloride (L-NAME; 30
mg/kg, nitric oxide synthase inhibitor), L-arginine (400 mg/kg,
nitric oxide precursor), or superoxide dismutase (SOD; 10,000U/kg,
oxygen-derived free radical scavenger). Data are reported as percent-
age change from basal time zero and expressed as mean  SEM. (a,
indicates significance at P 	 .05 compared to sham; b, indicates
significance at P 	 .05 compared with the IR group without drug
treatment; d, indicates significance at P 	 .05 compared with the
L-NAME group at P	 .05.)medullary blood flow after SMA-SRACR but completelyreversed the fall in medullary blood flow found after renal-
SRACR without drug treatment (Fig 2). These findings
suggest that endogenous renal NO and splanchnic vasodi-
lator prostanoid synthesis contribute to maintaining renal
medullary blood flow.
NO release was markedly decreased after SMA-SRACR
and renal-SRACR in the cortex and medulla (Fig 3, Fig 4).
Cortical and medullary NO release was restored with SOD
treatment in the SMA-SRACR but not in the renal-SRACR
groups (Fig 3, Fig 4). This finding suggests that ODFRs
generated duringmesenteric ischemia–reperfusion contrib-
uted to the loss of cortical andmedullary NO synthesis after
SMA-SRACR.
SMA-SRACR and renal SRACR increased cortical and
medullary release of PGE2 compared with the sham group,
which was abolished by the indomethacin controls (Fig 5,
Fig 6). L-arginine treatment of the SMA-SRACR and
renal-SRACR groups decreased cortical and medullary
PGE2 release back to the sham levels. L-NAME and SOD
did not alter PGE2 release in the cortex or medulla in any of
the groups (Fig 5, Fig 6). SMA-SRACR and renal-SRACR
did not induce any consistent changes in cortical or med-
ullary thromboxane B2 or 6-keto-PGF1 synthesis (Figs 7
to 10).
SMA-SRACR decreased cortical iNOS and PGI2 syn-
thase content but did not alter content of the any of the
0.0
0.5
1.0
1.5
RENAL
SMA
PG
E 2
 
(%
 
B
as
al
)
IR  IR+
Indo
   IR+
L-NAME
  IR+
L-Arg
a
Sham  IR+
SOD
a
a,b
a
a
b
b
a,b
b
b,d
Fig 6. The effect of superior mesenteric artery (SMA) suprarenal
aortic clamping and reperfusion (SRACR) and renal-SRACRon renal
medullary prostaglandinE2 (PGE2) release.Microdialysis probeswere
placed 2 mm into the cortex, connected to a syringe pump and
perfused in vivo at 3 L/min with lactated Ringer’s solution. Dialy-
sate fluid was collected at basal time zero, after 30 minutes of supra-
renal aortic clamping, followed by 60 minutes of reperfusion, and
compared with sham operation. The ischemia–reperfusion (IR)
groups (n  8 each) were treated with carrier, indomethacin (intra-
venous cyclooxygenase-1 and cyclooxygenase-2 inhibitor, 10 mg/
kg), N-nitro-L-arginine methyl ester hydrochloride (L-NAME; 30
mg/kg, nitric oxide synthase inhibitor), L-arginine (400 mg/kg,
nitric oxide precursor), or superoxide dismutase (SOD; 10,000U/kg,
oxygen-derived free radical scavenger). Data are reported as percent-
age change from basal time zero and are expressed as mean SEM.
(a, indicates significance at P 	 .05 compared to sham; b, indicates
significance at P 	 .05 compared with the IR group without drug
treatment; d, indicates significance at P 	 .05 compared with the
L-NAME group at P	 .05.)enzymes measured in the medulla (Table). Renal-SRACR
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only modestly in the medulla. No other enzyme changes
were noted in the cortex or the medulla after renal-SRACR
(Table).
SMA-SRACR caused a 90% decrease in the creatinine
clearance compared with the sham group, whereas renal-
SRACR caused a 60% decrease in creatinine clearance.
Treatment with indomethacin, SOD, L-NAME, or L-
arginine did not alter creatinine clearance after SMA-
SRACR or renal-SRACR (Fig 11).
DISCUSSION
The pathophysiology of the renal injury after repair of
suprarenal aortic pathology is not well understood.1-3 Sev-
eral animal studies have shown that clamping above the
renal arteries decreased total renal artery blood flow, glo-
merular filtration rate, urine flow, and fractional sodium
reabsorption, and caused an increase in renal vascular resis-
tance.34-36 Repair of suprarenal aortic pathology can in-
volve clamping the aorta above the renal arteries, the SMA,
or above the celiac arteries. To our knowledge, no study has
determined if clamping the aorta at different suprarenal
levels has differential effects on renal function and intrare-
nal blood flow.
Endogenous renal vasodilator eicosanoids and NO have
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Fig 7. The effect of superior mesenteric artery (SMA) suprarenal
aortic clamping and reperfusion (SRACR) and renal-SRACR on
renal cortical thromboxane B2 release. Microdialysis probes were
placed 2 mm into the cortex, connected to a syringe pump and
perfused in vivo at 3 L/min with lactated Ringer’s solution.
Dialysate fluid was collected at basal time zero, after 30 minutes of
suprarenal aortic clamping, followed by 60 minutes of reperfusion,
and compared with sham operation. The ischemia–reperfusion
(IR) groups (n  8 each) were treated with carrier, indomethacin
(intravenous cyclooxygenase-1 and cyclooxygenase-2 inhibitor, 10
mg/kg), N-nitro-L-arginine methyl ester hydrochloride (L-
NAME; 30 mg/kg, nitric oxide synthase inhibitor), L-arginine
(400 mg/kg, nitric oxide precursor), or superoxide dismutase
(SOD; 10,000 U/kg, oxygen-derived free radical scavenger). Data
are reported as percentage change from basal time zero and ex-
pressed as mean  SEM. (a, indicates significance at P 	 .05
compared with sham; b, indicates significance at P	 .05 compared
with the IR group without drug treatment at P 	 .05)been implicated as contributing to the regulation of renalblood flow in normal and pathophysiologic states. One study
has shown inhibition of COX or NOS was shown to increase
renal vascular resistance after renal ischemia–reperfusion, im-
plying that vasodilator eicosanoids and NO were important
mediators involvedwithmaintenance of renal blood flow after
renal ischemia–reperfusion injury.16
Decreased synthesis of renal vasodilator prostanoids
(PGE2 and PGI2) has been associated with renal vasocon-
striction.11-16 The loss of endogenous renal vasodilator
prostanoids has been shown after a number of injuries,
including renal ischemia–reperfusion injury15-17 and intes-
tinal ischemia–reperfusion injury.15,37,38
NO is another potent endogenous renal vasodilator
that has been shown to contribute to the maintenance of
normal renal blood flow and function under normal phys-
iologic conditions.4-10 Zou and Crowley39 used an in vivo
microdialysis technique to show that NO was synthesized
in both the renal cortex and medulla. They concluded that
NO may play a role in the control of vascular tone and
tubular function in the kidney.39 Loss of endogenous
renal NO synthesis has been suggested to contribute to
renal vasoconstriction after renal ischemia–reperfusion
injury.4-10,16,17,39
Our laboratory has recently shown that SMA-SRACR
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Fig 8. The effect of superior mesenteric artery (SMA) suprare-
nal aortic clamping and reperfusion (SRACR) and renal-SRACR
on renal medullary thromboxane B2 release. Microdialysis
probes were placed 2 mm into the cortex, connected to a syringe
pump and perfused in vivo at 3 L/min with lactated ringer’s
solution. Dialysate fluid was collected at basal time zero, after
30 minutes of supra-renal aortic clamping, followed by 60
minutes of reperfusion, and compared with sham operation.
The ischemia–reperfusion (IR) groups (n  8 each) were
treated with carrier, indomethacin (intravenous cyclooxygen-
ase-1 and cyclooxygenase-2 inhibitor, 10 mg/kg), N-nitro-L-
arginine methyl ester hydrochloride (L-NAME; 30 mg/kg,
nitric oxide synthase inhibitor), L-arginine (400 mg/kg, nitric
oxide precursor), or superoxide dismutase (SOD; 10,000 U/kg,
oxygen-derived free radical scavenger). Data are reported as
percentage change from basal time zero and expressed as mean
 SEM. (a, indicates significance at P 	 .05 compared with
sham; b, indicates significance at P 	 .05 compared with the IR
group without drug treatment; d, indicates significance at P 	
.05 compared with the L-NAME group at P 	 .05.)caused a marked decrease in medullary and cortical blood
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lary and cortical NO synthesis and serum creatinine clear-
ance.19 None of these previous studies have examined the
possible differential effects of renal-SRACR on intrarenal
blood flow, endogenous renal PGE2, PGI2, or NO synthe-
sis, or renal function compared with SMA-SRACR.
ODFRs have been implicated in the pathogenesis of
renal ischemia–reperfusion injury. During the phase of
ischemia, hypoxanthine and xanthine are produced after
degradation of adenosine triphosphate and xanthine dehy-
drogenase is converted to xanthine oxidase.23,40,41 During
the phase of reperfusion, molecular oxygen purines are
metabolized by xanthine oxidase, leading to superoxide
radical production. This may then be converted by SOD to
hydrogen peroxide, which is then degraded to water and
oxygen by the enzyme catalase. Superoxide anions can also
react with hydrogen peroxide in the presence of iron to
form the highly reactive hydroxyl radicals. All of the ODFR
species can react with protein, nucleic acids, or lipids,
leading to renal damage.23,42-46 To our knowledge, no
studies have determined if ODFRs contribute to renal
dysfunction after renal-SRACR as had been previously
shown after SMA-SRACR.20
In the present study, both SMA-SRACR and renal-
SRACR decreased renal cortical and medullary blood flow
and NO synthesis. SOD treatment reversed the fall in
cortical blood flow after SMA-SRACR and cortical and
medullary NO synthesis after SMA-SRACR. This finding
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Fig 9. The effect of superior mesenteric artery (SMA) suprarenal
aortic clamping and reperfusion (SRACR) and renal-SRACRon renal
cortical prostaglandin I2 (PGI2) (6-keto-PGF1) release. Microdialy-
sis probes were placed 2 mm into the cortex, connected to a syringe
pump and perfused in vivo at 3 L/min with lactated Ringer’s
solution. Dialysate fluid was collected at basal time zero, after 30
minutes of suprarenal aortic clamping, followed by 60 minutes of
reperfusion, and compared with sham operation. The ischemia–
reperfusion (IR) groups (n  8 each) were treated with carrier,
indomethacin (intravenous cyclooxygenase-1 and cyclooxygenase-2
inhibitor, 10 mg/kg), N-nitro-L-arginine methyl ester hydrochlo-
ride (L-NAME; 30 mg/kg, nitric oxide synthase inhibitor), L-
arginine (400 mg/kg, nitric oxide precursor), or superoxide dis-
mutase (SOD; 10,000 U/kg, oxygen-derived free radical scavenger).
Data are reported as percentage change from basal time zero and
expressed as mean  SEM. (a, indicates significance at P 	 .05
compared with sham.)suggested that ODFRs contributed to decreased corticalblood flow after SMA-SRACR, which could be partly due
to decreased endogenous cortical NO synthesis. The West-
ern blot data suggested that a decrease in cortical iNOS
content contributed to the fall in cortical NO synthesis after
SMA-SRACR.
Indomethacin treatment significantly decreased corti-
cal and medullary blood flow after SMA-SRACR but not
renal-SRACR. This finding suggests that the deleterious
effect of indomethacin occurs in the mesenteric bed and
not the renal cortex or medulla. Previous studies have
shown that endogenous splanchnic PGI2 is the primary
endogenous vasodilator in the splanchnic bed. Ischemia–
reperfusion of the mesenteric bed leads to ODFR down-
regulation of splanchnic PGI2 synthesis and decreased
splanchnic blood flow. From these studies and from the
current findings, we hypothesize that SMA-SRACR, similar
to the studies examining splanchnic ischemia–reperfusion,
caused a loss of endogenous splanchnic PGI2 that contrib-
uted to local and systemic ODFR generation, which has
profound influences on both splanchnic and renal cortical
blood flow. The increase in the cortical and medullary
synthesis of PGE2, a potent renal vasodilator, after SMA-
SRACR and renal-SRACR appears to be an endogenous
intrarenal mechanism to compensate for the loss of endog-
enous NO, the primary intrarenal vasodilator. The mecha-
nism for the increased cortical and medullary PGE2 could
be partly due to an increase in COX-2 content.
SMA-SRACR and renal-SRACR both markedly de-
creased creatinine clearance. The 90% fall in creatinine
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Fig 10. The effect of superior mesenteric artery (SMA) suprarenal
aortic clamping and reperfusion (SRACR) and renal-SRACRon renal
medullary prostaglandin I2 (PGI2)(6-keto-PGF1) release. Microdi-
alysis probeswere placed 2mm into the cortex, connected to a syringe
pump and perfused in vivo at 3 L/min with lactated ringer’s solu-
tion. Dialysate fluid was collected at basal time zero, after 30 minutes
of supra-renal aortic clamping, followed by 60minutes of reperfusion
and compared with sham operation. The ischemia–reperfusion (IR)
groups (n  8 each) were treated with carrier, indomethacin (intra-
venous cyclooxygenase-1 and cyclooxygenase-2 inhibitor, 10 mg/
kg), N-nitro-L-arginine methyl ester hydrochloride (L-NAME; 30
mg/kg, nitric oxide synthase inhibitor), L-arginine (400 mg/kg,
nitric oxide precursor), or superoxide dismutase (SOD; 10,000U/kg,
oxygen-derived free radical scavenger; n  8). Data are reported as
percentage change from basal time zero and expressed as mean 
SEM. (a, indicates significance at P	 .05 compared with sham.)clearance after SMA-SRACR was significantly lower than
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SRACR. These data support the notion that although both
models cause severe renal injury, the renal injury after
SMA-SRACR is much more severe than the renal injury
after renal-SRACR. These findings also suggest that clamp-
ing the aorta above the SMAor renal arteries for 30minutes
is a severe physiologic insult to the kidney and that other
Table. The effect of suprarenal and superior mesenteric ar
endogenous mediators
Renal SRACR
Cortex Med
iNOS
Sham 164  20 675 
I-R 203  26 763 
COX-2
Sham 328  23 533 
I-R 716  37* 618 
PGE2
Sham 422  53 2407 
I-R 547  66 2344 
PGI2
Sham 1401  61 1961 
I-R 1370  55 1841 
SRACR, Suprarenal and aortic clamping and reperfusion; SMA, superior
PGE2, prostaglandin E2; PGI2, prostacyclin I2.
*These values are significant.
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Fig 11. The effect of superior mesenteric artery (SMA) suprare-
nal aortic clamping and reperfusion (SRACR) and renal-SRACR
on creatinine clearance (Cr Cl). Serum and urine were collected
from separate groups of animals to measure serum creatinine, urine
creatinine, and urine volume to calculate creatinine clearance. The
serum and urine were collected at basal time zero and after 30
minutes of supra-renal aortic clamping, followed by 60 minutes of
reperfusion and compared with sham operation. The ischemia–
reperfusion (IR) groups (n  8 each) were treated with carrier,
indomethacin (intravenous cyclooxygenase-1 and cyclooxygenase-2
inhibitor, 10 mg/kg), N-nitro-L-arginine methyl ester hydrochlo-
ride (L-NAME; 30 mg/kg, nitric oxide synthase inhibitor), L-
arginine (400 mg/kg, nitric oxide precursor), or superoxide dis-
mutase (SOD; 10,000 U/kg, oxygen-derived free radical scavenger).
Data are reported as percentage change from basal time zero and
expressed as mean  SEM. (a, indicates significance at P 	 .05
compared with sham; e, indicates significance at P 	 .05 compared
with the renal-SRACR group.)factors not investigated in this study also contribute todecreased renal function after SMA-SRACR and renal-
SRACR.
The inability of SOD treatment to reverse or lessen the
profound decreases in medullary blood flow after SMA-
SRACR shows that there are several limitations of this
study. The use of SOD does not address the role of other
oxygen radical species that may be exerting an effect in this
model.
A second limitation is the use of male animals; there-
fore, the study does not investigate if the changes found are
affected by sex. Our previous studies have used male ani-
mals, and we have chosen to continue to use male animals
to provide continuity of our studies.19,20
A third limitation is the placement of the aortic clamp
above the SMA and renal arteries and not above the celiac
artery (supraceliac artery clamping is more commonly used
in our patients). Supra-SMA and renal clamping in the rat is
quite easy and avoids manipulation of the viscera, especially
the liver; whereas, supraceliac clamping is difficult, requires
manipulation of the viscera, and involves more time and
trauma to the animal.
CONCLUSION
This study supports our previous work showing that
NO is important in maintaining renal cortical and medul-
lary blood flow and function. These data also support the
hypothesis that the loss of medullary and cortical microvas-
cular blood flow after SMA-SRACR and renal-SRACR is
from different mechanisms. The ODFRs generated after
SMA-SRACR, which could be generated locally in the
kidney or generated in the splanchnic bed, contribute to
downstream renal dysfunction.15
These data also suggest that we need to expand the
scope of our studies to determine the other inflammatory
mediators and ODFR species that contribute to the loss of
endogenous renal NO, blood flow, and function after
aortic clamping and reperfusion on renal content of
SMA SRACR
Cortex Medulla
164  22 675  22
106  20* 684  44
328  23* 533  42
572  61 606  75
422  53 2407  64
495  85 2720  160
1401  60 1961  37
1069  47* 1815  77
teric artery; iNOS, inducible nitric oxide synthase; COX, cyclooxygenase;tery
ulla
22
29
42
28
64
110
37
44
mesenSMA-SRACR and renal-SRACR. Identification of factors
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Volume 45, Number 2 Myers, Wang, and Myers 365responsible for maintaining renal microvascular blood flow
will allow development of treatment strategies that will help
maintain renal microvascular blood flow in the treatment of
complex aortic pathology that requires suprarenal aortic
clamping during the aortic reconstruction.
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